Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 2,208 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Radiation Treatment for Tumors Clear all

Conditions: Pancreatic Cancer
Interventions: fluorouracil, gemcitabine hydrochloride, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 106
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 66 more

Conditions: Pleural Neoplasms
Interventions: pemetrexed, cisplatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 7
States / cities: San Francisco, California • Chicago, Illinois • Baltimore, Maryland + 4 more

Conditions: Diagnostic Imaging
Interventions: BAY1075553; Drug
Lead sponsor: Lantheus Biosciences Ltd.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Merkel Cell Carcinoma, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
Interventions: Ipilimumab, Nivolumab, Radiation Therapy; Biological · Radiation
Lead sponsor: Claire Verschraegen; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Head and Neck Cancer
Interventions: capecitabine, carboplatin, conventional surgery, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Brain Metastases
Interventions: Cohort A, Cohort B; Radiation
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 3
States / cities: Indianapolis, Indiana

Conditions: Radiation Therapy, Virtual Reality
Interventions: standard of care, Virtual Reality Intervention, Radiation Therapist Survey; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Uveal Melanoma, Radiation Retinopathy, Radiation Maculopathy
Interventions: Ranibizumab; Drug
Lead sponsor: Shields, Shields and Associates; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Response-driven Adaptive Radiation Therapy, Carboplatin, Paclitaxel, FDG-PET, V/Q SPECT, Durvalumab; Radiation · Drug · Device
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Ann Arbor, Michigan

Conditions: Hepatocellular Carcinoma
Interventions: Prednisone; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Uterine Cervical Neoplasms
Interventions: [F18]Fluorothymidine; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Non Small Cell Lung Cancer
Interventions: Image Guided Stereotactic Ablative Radiotherapy; Radiation
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Melanoma
Interventions: A-dmDT390-bisFv(UCHT1) (Resimmune®), Ionizing Radiation; Drug · Radiation
Lead sponsor: Virogen Biotechnology Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Squamous Cell Carcinomas
Interventions: Reduced Dose Radiation, Standard Dose Radiation, Carboplatin; Radiation · Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2035
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: brachytherapy, hypofractionated radiation therapy, image-guided radiation therapy, intensity-modulated radiation therapy; Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Lung Cancer (NSCLC), Radiation
Interventions: MRI; Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: Non-contrast Computed Tomography (CT) Scans (Metallic Markers), Non-contrast CT Scans (Metallic Markers); Device
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Magnetic Resonance Imaging, Memantine Hydrochloride, Neurocognitive Assessment, Stereotactic Radiosurgery, Survey Administration, Whole-Brain Radiotherapy; Procedure · Drug · Other + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 227
States / cities: Phoenix, Arizona • Anaheim, California • Bellflower, California + 172 more

Conditions: Cervical Cancer, Endometrial Cancer, Radiation Toxicity, Sexuality and Reproductive Issues
Interventions: compliance monitoring, questionnaire administration, assessment of therapy complications, management of therapy complications, psychosocial assessment and care; Behavioral · Other · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 8
States / cities: Cleveland, Ohio

Conditions: Locally Advanced Rectal Carcinoma, Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage IIC Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
Interventions: Capecitabine, Fluorouracil, Intensity-Modulated Radiation Therapy, Leucovorin, Oxaliplatin, Quality-of-Life Assessment, Surveillance, Total Mesorectal Excision; Drug · Radiation · Other + 2 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: bortezomib, fludarabine phosphate, melphalan, total marrow irradiation, tacrolimus, sirolimus, peripheral blood stem cell transplantation, laboratory biomarker analysis; Drug · Other · Radiation + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Duarte, California

Conditions: Renal Cancers
Interventions: Stereotactic Ablative Radiation Therapy; Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Enteritis
Interventions: SGX201 (delayed release beclomethasone 17,21-dipropionate); Drug
Lead sponsor: Soligenix; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Chicago, Illinois • Boston, Massachusetts

Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Paranasal Sinus Squamous Cell Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Major Salivary Gland Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Sinonasal Cancer AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8, Unresectable Head and Neck Cutaneous Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Hypopharyngeal Squamous Cell Carcinoma, Unresectable Laryngeal Squamous Cell Carcinoma, Unresectable Oral Cavity Squamous Cell Carcinoma, Unresectable Oropharyngeal Squamous Cell Carcinoma, Unresectable Paranasal Sinus Squamous Cell Carcinoma, Unresectable Salivary Gland Squamous Cell Carcinoma
Interventions: Biospecimen Collection, Computed Tomography, Elimusertib, Pembrolizumab, Positron Emission Tomography, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy; Procedure · Drug · Biological + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 11
States / cities: Los Angeles, California • Chicago, Illinois • Ann Arbor, Michigan + 6 more

Search by objective public record fields.

Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas

Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma

PET/CT (Positron Emission Tomography/Computed Tomography) Imaging for Safety and Tolerability and Diagnostic Performance of BAY1075553 in Patients With Prostate Cancer and Healthy Volunteers

Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer

Carboplatin, Capecitabine, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Pilot Phase 2 Study Whole Brain Radiation Therapy With Simultaneous Integrated Boost for Patients With Brain Metastases

Effectiveness of Virtual Reality (VR) in the Management of Anxiety for Patients Undergoing Radiotherapy

Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy

A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer

A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

FLT PET Imaging for Cervical Cancer

Phase II Image Guided Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer

A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma

The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer

Internal Radiation Therapy With or Without External-Beam Radiation Therapy in Treating Patients With Localized Prostate Cancer

GCC 2546- Motion Management

Pilot Study to Validate Metallic Markers for Image Guided Radiation Therapy for Breast Cancer Tx

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer

Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

Stereotactic Ablative Body Radiation Therapy for Patients With Primary Renal Cancer

A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer